| Median (Q1, Q3)† | Median (Q1, Q3) | Median (Q1, Q3) | Test Statistic | p-Value |
Baseline Duration | 3 (1, 7) | 3 (2, 6) | 5 (2, 7) | | 0.56 |
Lifetime duration | 7 (4, 9) | 8 (5, 10) | 10 (7, 14)*,‡,§ | | 0.01 |
| Mean±SD | Mean±SD | Mean±SD | | |
Baseline # of symptoms | 5.5±1.3 | 5.8±1.1 | 6.3±0.9*,‡ | F2, 65=3.41 | 0.04 |
Lifetime # of symptoms | 6.1±0.9 | 6.0±1.0 | 6.7±0.7*,‡,§,** | F2, 65=5.25 | 0.008 |
| N (%) | N (%) | N (%) | | |
Baseline ultra-rapid or ultradian cycling | 5 (38) | 5 (24) | 13 (39) | | 0.48 |
Lifetime ultra-rapid or ultradian cycling | 7 (54) | 8 (38) | 22 (65) | | 0.17 |
Severe impairment at baseline | 7 (54) | 14 (67) | 25 (74) | | 0.44 |